The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACRX | +41.76% | -95.84% | -47.05% | -99% |
| S&P | +14.49% | +91.09% | +13.83% | +415% |
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Gross Margin | 65.84% | 0.0% |
| Market Cap | $40.72M | 179.7% |
| Market Cap / Employee | $3.13M | 0.0% |
| Employees | 13 | -13.3% |
| Net Income | -$4.44M | -32.3% |
| EBITDA | -$3.42M | 8.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.46M | -68.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.50M | -0.4% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.15% | 22.5% |
| Return On Invested Capital | -26.46% | -18.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.51M | 14.5% |
| Operating Free Cash Flow | -$2.51M | 14.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.93 | 1.05 | 1.41 | 2.77 | 141.90% |
| Price to Sales | 58.59 | 79.91 | 481.58 | 588.55 | 1404.68% |
| Price to Tangible Book Value | 0.93 | 1.05 | 1.41 | 2.77 | 141.90% |
| Enterprise Value to EBITDA | -5.96 | -1.68 | -3.83 | -4.56 | 8.00% |
| Return on Equity | -117.7% | -106.8% | -117.6% | -86.5% | -22.73% |
| Total Debt | $0.00M | $6.53M | $6.50M | $6.50M | -0.43% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
